Chronic Obstructive Pulmonary Disease (COPD) Market by Type, Distribution Channel & Region | Forecast 2023 to 2033
A rise in prevalence of COPD diseases, coupled with a well-developed healthcare infrastructure are the major factors that are anticipated to escalate the market growth during the forecast period.
Chronic Obstructive Pulmonary Disease (COPD) Market Snapshot (2023 to 2033)
The global Chronic Obstructive Pulmonary Disease (COPD) market size is expected to be valued at US$ 21.58 Billion in 2023. With the increasing alcohol consumption among people, the overall demand for Chronic Obstructive Pulmonary Disease (COPD) is projected to grow at a CAGR of 4.4% between 2023 and 2033, totaling around US$ 33.19 Billion by 2033.
Data Points
Key Statistics
Chronic Obstructive Pulmonary Disease (COPD) Market Value 2023
US$ 21.58 Billion
Chronic Obstructive Pulmonary Disease (COPD) Market Projected Value (2033)
US$ 33.19 Billion
Chronic Obstructive Pulmonary Disease (COPD) Market CAGR (2023 to 2033)
4.4%
According to the analysis of Future Market Insights, the Chronic Obstructive Pulmonary Disease (COPD) market is expected to fuel over the analysis period, attributed to an increase in patient population, due to a substantial rise in incidence as well as the prevalence of asthma.
As per a 2021 factsheet from the World Health Organization (WHO), asthma is a major non-communicable disease (NCD), affecting both children as well as adults. Globally, it affected an estimated 262 million people in 2019 and caused 461,000 deaths.
Enormous investments in the study of asthma drugs, accompanied by strategic collaborations such as mergers and acquisitions are the business strategies followed by the major companies in the market. Hence, the aforementioned factors are anticipated to boost the growth of the COPD market during the forecast period.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Chronic Obstructive Pulmonary Disease (COPD) Demand Analysis (2018 to 2022) Vs Market Outlook (2023 to 2033)
The global demand for Chronic Obstructive Pulmonary Disease (COPD) is projected to increase at a CAGR of 4.4% during the forecast period between 2023 and 2033, reaching a total of US$ 33.19 Billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 2.4%.
According to Future Market Insights, a market research and competitive intelligence provider, the Chronic Obstructive Pulmonary Disease (COPD) market was valued at US$ 20.67 Billion in 2022.
As per a March 2021 study by José Luis Izquierdo et al., published in the European Respiratory Journal, allergy-related factors such as eczema and rhinitis were less common in asthmatic patients with COVID-19. Though, there was a high prevalence of these comorbidities observed in patients with COVID-19, who required hospital admission.
The continual rise in the geriatric population worldwide is a major factor driving market growth. As the World Ageing 2020 report, in 2020, there were around 727 million people aged 65 years or more in the world. In addition, the number of older persons is projected to double to 1.5 billion in 2050. Globally, the share of the population aged 65 years or over increased from 9.3% in 2020 to reach 16% by 2050. Thus, the growing geriatric population is likely to fuel the market growth during the analysis period, owing to the fact that asthma is a widely prevalent disease found in people over the age of 65.
Moreover, technological advancements are another major factor that is projected to create lucrative avenues for market growth. Also, limitations of traditional treatments, such as the late onset of action as well as low efficacy, are anticipated to encourage the development of novel targeted drugs, which in turn are propelling market growth.
Which Drivers underpin Chronic Obstructive Pulmonary Disease (COPD) Industry Expansion?
Awareness Efforts by Individual Organizations to Fuel the Market Growth
As per a 2019 study published by the National Center for Biotechnology Information, globally, 212.3 million prevalent cases of chronic obstructive pulmonary disease (COPD) were reported, with COPD accounting for 3.3 million deaths and 74.4 million disability-adjusted life years. In addition, as per the American Lung Association, in 2018, 9.0 million adults, or 3.6% of those aged 18 or older, had chronic bronchitis. In 2018, 16.4 million people, or 6.6% of adults, reported a diagnosis of any type of COPD (chronic bronchitis, emphysema, or COPD). Hence, the rise in the incidence of chronic obstructive pulmonary disease is anticipated to augment the market growth in the near future.
Additionally, in November 2021, as per the data published by the National Heart, Lung and Blood Institute, each November, the chronic obstructive pulmonary disease (COPD) community comes together to promote a better understanding of COPD, a progressive lung disease that affects millions across the US. Further, rising awareness among the people, regarding chronic obstructive pulmonary disease (COPD) and its symptoms is important as early diagnosis, as well as treatment can improve quality of life.
Rise in Adoption of More Effective Combination Therapy to Accelerate the Market Growth
The combination therapies include LABA-ICS, triple therapy, LAMA-ICS, and other combination drugs. The adoption of combination therapy is surging, as it is more effective than the separate use of bronchodilators and corticosteroids. Moreover, a rise in the number of patients successfully treated with combination therapy, who were not showing signs of recovery with bronchodilators or corticosteroid treatments is a major factor that is projected to accelerate the global chronic obstructive pulmonary disease market in the forthcoming years. Also, combination therapy is considered to be more effective than monotherapy for improving symptoms as well as the quality of life.
Find your sweet spots for generating winning opportunities in this market.
Which Factors are limiting the Growth of Chronic Obstructive Pulmonary Disease (COPD) Market?
The Side Effects of COPD Drugs to Restrain the Market Growth
The side effect of the drugs used in treating chronic obstructive pulmonary disease is one of the major factors hindering the growth of the COPD market during the analysis period. For instance, as per the data published by the National Center for Biotechnology Information, there are some serve side effects associated with the drugs that are used in the treatment of chronic obstructive pulmonary disease, namely oral infections, bruising, and hoarseness.
Moreover, these medications are useful for people with frequent exacerbations of Chronic Obstructive Pulmonary Disease. An instance of inhaled steroids includes Fluticasone (Flovent HFA). Also, respiratory infections are observed in people with COPD, who are more likely to catch flu, colds, and pneumonia. Chronic Obstructive Pulmonary Disease can cause many complications like depression, heart problems, high blood pressure in lung arteries, and lung cancer in some cases.
Challenges of New Drug Development to Limit the Market Growth
Drug failures (termination) in clinical trials as well as the development of new drugs are challenging tasks that are anticipated to impede the growth of the COPD market in the near future. For instance, in May 2019, benralizumab, an asthma drug failed to decrease annual COPD exacerbation rates for patients with moderate to very severe COPD.
Additionally, the Phase III, randomized, placebo-controlled, double-blind, parallel-group clinical trials TERRANOVA and GALATHEA evaluated the efficacy and safety of benralizumab, for the prevention of exacerbations in patients with moderate to very severe COPD.
Region-wise Insights
Will North America Continue Dominance in the Global Chronic Obstructive Pulmonary Disease (COPD) Market?
Well-Structured Healthcare Industry in the Region to Fuel the Market Growth
The Chronic Obstructive Pulmonary Disease (COPD) Market in North America is expected to accumulate the highest market share of 44% in 2023.
The regional market growth is attributed to the factors such as the availability of well-defined reimbursement policies from private and public health insurance firms, and the highly structured healthcare industry in the region. Moreover, the presence of a large number of players in North America, coupled with an increase in research & development activities to provide advanced and efficient products, are other factors boosting the growth of the COPD market in the region.
As per the Lung Association, COPD is prevalent in men and women and is the sixth most common factor of hospitalization in women and fourth most in men in Canada. The market is also driven by factors including the rapid pace of industrialization, exponentially increasing air pollution, and the adoption of a sedentary lifestyle in the region. Also, lack of awareness of COPD, and the increasing smoking population are other factors that are likely to escalate the regional market growth during the forecast period. The region is expected to hold the highest CAGR of 4.3% during the forecast period.
How Will the Growth of the Chronic Obstructive Pulmonary Disease (COPD) Market unfold in Asia Pacific?
Increase in Geriatric Population in the Region to Fuel the Market Growth
The Chronic Obstructive Pulmonary Disease (COPD) Market in Asia Pacific is expected to accumulate the second-highest market share of 43% in 2023.
Asia Pacific has a relatively untapped chronic obstructive pulmonary disease treatment market, compared to the developed regions such as North America and Europe. Therefore, the region offers lucrative opportunities to COPD market players. Factors such as a surge in the geriatric population, high incidence of chronic obstructive pulmonary disease, and rise in patient population are expected to fuel the COPD market in the region.
Furthermore, the Asia Pacific COPD market is largely driven by the rising prevalence of respiratory distress conditions. For instance, as per the data published by the World Health Organization (WHO), due to COPD, more than 90% of deaths occur in low and middle-income countries. Rapid urbanization that causes an increase in air pollution provides amplifies the predisposition to acquire respiratory diseases like COPD, thus creating significant avenues for the COPD drugs market in the region. Asia Pacific is expected to hold the highest CAGR of 4.2% during the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-wise Insights
By Drug Class, which Chronic Obstructive Pulmonary Disease (COPD) Category will remain prominent?
Combination Therapy Segment to beat Competition in Untiring Market
On the basis of drug class, the global Chronic Obstructive Pulmonary Disease (COPD) market is dominated by the Combination Therapy Segment, which accounts for a share of 45%. The segment is expected to hold a CAGR of 4.3% over the analysis period.
The segment is expected to dominate the global market over the analysis period, attributed to the increase in the efficacy of combination therapy in COPD treatment. In addition, an increase in the success rate of combination therapy in COPD treatment, and recent regulatory approvals are anticipated to propel the adoption of combination therapy.
By Type, which Chronic Obstructive Pulmonary Disease (COPD) Category dominates?
Chronic Bronchitis Segment to Drive the Chronic Obstructive Pulmonary Disease (COPD) Market
Based on the Type, the chronic bronchitis segment is expected to witness a significant growth of 43% in 2022, and the trend is expected to continue during the forecast period, expanding at a rapid rate of 4.2% CAGR over the analysis period.
The segment’s growth is attributed to the factors such as the fact that chronic bronchitis is a group of lung diseases that causes airflow blockage and breathing issues. It is widespread among smokers and rising at a rapid pace. Hence, an upsurge in breathing issues among smokers, coupled with a rise in airflow blockage is a major factor fueling the segment’s growth during the forecast period.
By Distribution Channel, which Chronic Obstructive Pulmonary Disease (COPD) Category dominates?
Retail Pharmacies Segment to Drive the Chronic Obstructive Pulmonary Disease (COPD) Market
Based on the Distribution Channel, the retail pharmacies segment is expected to witness a significant growth of 42% in 2022, and the trend is expected to continue during the forecast period, expanding at a rapid rate of 4.2% CAGR over the analysis period.
The segment is expected to grow at a rapid pace in the forthcoming years, owing to the factors such as an increase in the number of retail pharmacies in developing countries, as well as an increase in the number of COPD therapeutics dispensed through retail pharmacies.
The Start-Up Ecosystem: How key Players are opening Frontiers for Future Growth?
Chronic Obstructive Pulmonary Disease (COPD) Market startup players are adopting various marketing strategies such as new product launches, geographical expansion, mergers and acquisitions, partnerships, and collaboration to identify the interest of potential patients and create a larger customer base. For instance,
Founded in 2015, Chance Pharmaceuticals is a developer of transformative inhalation therapies for pulmonology disorders. The company's lead candidate CXF11 is a tiotropium bromide inhalation drug for the prevention of bronchospasm in patients with chronic obstructive pulmonary disease. In addition, developing an inhaler to disperse powder and deliver particles to the lung.
Synspira, a startup established in 2017, is developing a novel class of inhalable glycopolymer-based therapeutics for pulmonary diseases including cystic fibrosis, chronic obstructive pulmonary disease (COPD), and pneumonia. The company has an exclusive license from Synedgen to the Glycomics Technology Platform for the development of inhaled glycopolymer-based therapeutics in pulmonary indications. Its drug pipeline includes SNSP 113 to improve the lung function of cystic fibrosis (preclinical) patients, SNSP 115 to treat pneumonia (preclinical), and SNSP 146 to treat COPD (preclinical). The company is using proprietary modified polysaccharide molecules to disrupt bacterial biofilms and to help expectorate mucus, exposing otherwise protected bacteria to antibiotics.
Started in 2016, Suzhou Xinmaide is a developer of drug-delivery devices for the treatment of respiratory diseases. The company's products include single-dose capsule DPI devices, multi-dose blister DPI devices, soft mist inhalation devices, and multi-power nasal spray devices for the delivery of drugs for diseases such as asthma, chronic obstructive pulmonary disease (COPD), nose and brain.
Who are the Leading Players in the Chronic Obstructive Pulmonary Disease (COPD) Market?
Prominent players in the Chronic Obstructive Pulmonary Disease (COPD) market are Almirall, AstraZeneca, Boehringer Ingelheim International GmbH, CHIESI Farmaceutici S.p.A., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc., Kyowa Hakko Kirin, Mylan N.V., Novartis AG, Orion Corporation, Sanofi, Sunovion Pharmaceuticals, Inc. (Sumitomo Dainippon Pharma Co., Ltd.), Teva Pharmaceutical Industries Ltd., Theravance Biopharma, and Verona Pharmaceuticals, among others.
Recent Developments:
In January 2022, the first patient was enrolled in a phase 4 study comparing Yupelri (revefenacin) to Spiriva (tiotropium) in improving lung health in adults with severe chronic obstructive pulmonary disease (COPD). The safety of these two approved once-daily COPD maintenance treatments would be assessed as well. Yupelri is a bronchodilator, a type of medication that relaxes and widens the lung airways, making breathing easier. It was developed by Theravance Biopharma and Mylan (now part of Viatris). It is available as an inhalable solution via a nebulizer, a small machine that turns liquid into a fine mist.
InNovember 2021, AstraZeneca announced that it had sold rights to sell Tudorza, also known as Eklira abroad, and Duaklir to the Switzerland-based pharmaceutical company Covis Pharma Group for US$ 270 Mn. These products are indicated for the treatment of chronic obstructive pulmonary disease (COPD).
In October 2021, Mylan Pharmaceuticals received FDA approval for its investigational new drug application (ANDA) for Breyna (budesonide and formoterol fumarate dihydrate inhalation aerosol), the first approved generic version of AstraZeneca's Symbicort. It is anticipated to be available in dosage strengths of 160 mcg/4.5 mcg and 80 mcg/4.5 mcg for patients with asthma or chronic obstructive pulmonary disease (COPD).
Report Scope
Report Attribute
Details
Growth Rate
CAGR of 4.4% from 2023 to 2033
Market Value in 2023
US$ 21.58 Billion
Market Value in 2033
US$ 33.19 Billion
Base Year for Estimation
2022
Historical Data
2018 to 2022
Forecast Period
2023 to 2033
Quantitative Units
Revenue in US$ Billion and CAGR from 2023 to 2033
Report Coverage
Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
Drug Class
Type
Distribution Channel
Region
Regions Covered
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Countries Profiled
The US
Canada
Brazil
Mexico
Germany
The UK
France
Spain
Italy
China
Japan
South Korea
Malaysia
Singapore
Australia
New Zealand
GCC
South Africa
Israel
Key Companies Profiled
Almirall
AstraZeneca
Boehringer Ingelheim International GmbH
CHIESI Farmaceutici S.p.A.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline plc
Kyowa Hakko Kirin
Mylan N.V.
Novartis AG
Orion Corporation
Sanofi
Sunovion Pharmaceuticals, Inc. (Sumitomo Dainippon Pharma Co., Ltd.)
Teva Pharmaceutical Industries Ltd.
Theravance Biopharma
Verona Pharmaceuticals
Key Segments Covered in the Chronic Obstructive Pulmonary Disease (COPD) Industry Analysis
Chronic Obstructive Pulmonary Disease (COPD) Market by Drug Class:
Combination Therapy
Bronchodilators
Corticosteroids
Phosphodiesterase Type 4 Inhibitor
Mucokinetics
Others
Chronic Obstructive Pulmonary Disease (COPD) Market by Type:
Chronic Bronchitis
Emphysema
Chronic Obstructive Pulmonary Disease (COPD) Market by Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Chronic Obstructive Pulmonary Disease (COPD) Market by Region:
North America
Europe
Asia Pacific
Latin America
Middle East & Africa
Frequently Asked Questions
What was the market value for Chronic Obstructive Pulmonary Disease (COPD) in 2022?
As of 2022, the market for Chronic Obstructive Pulmonary Disease (COPD) was valued at US$ 20.67 Billion, as per FMI
At what value did the Chronic Obstructive Pulmonary Disease (COPD) Market close in 2023?
By 2023-end, sales of Chronic Obstructive Pulmonary Disease (COPD) closed at a value of US$ 21.58 Billion
What was the last 4 years value CAGR for Chronic Obstructive Pulmonary Disease (COPD)?
From 2018 to 2022, Chronic Obstructive Pulmonary Disease (COPD) demand expanded at a CAGR of 2.4%
What is the projected forecast CAGR for the Chronic Obstructive Pulmonary Disease (COPD) Industry from 2023 to 2033?
From 2023 to 2033, Chronic Obstructive Pulmonary Disease (COPD) sales are expected to flourish at a CAGR of 4.4%
According to FMI, what is the anticipated market value for Chronic Obstructive Pulmonary Disease (COPD) in 2033?
By 2033, the market value of Chronic Obstructive Pulmonary Disease (COPD) is expected to reach US$ 33.19 Billion.
By Type, which category ranks first with regard to Chronic Obstructive Pulmonary Disease (COPD)?
By Type, the Chronic Bronchitis segment constitutes the bulk of the market share of 43% in 2022.
By Distribution Channel, which category ranks first with regard to Chronic Obstructive Pulmonary Disease (COPD)?
By Distribution Channel, the Retail Pharmacies segment dominates the market with a share of 42% in 2022.
Table of Content
1. Executive Summary | Chronic Obstructive Pulmonary Disease (COPD) Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Billion) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Billion) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By COPD Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Billion) Analysis By COPD Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Billion) Analysis and Forecast By COPD Type, 2023 to 2033
5.3.1. Emphysema
5.3.2. Chronic Bronchitis
5.4. Y-o-Y Growth Trend Analysis By COPD Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By COPD Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Billion) Analysis By Treatment Type, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Billion) Analysis and Forecast By Treatment Type, 2023 to 2033
6.3.1. Drugs
6.3.2. Surgery
6.3.3. Oxygen Therapy
6.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Treatment Type, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Billion) Analysis By End User, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Billion) Analysis and Forecast By End User, 2023 to 2033
7.3.1. Hospitals & Clinics
7.3.2. Home Care Settings
7.3.3. Others
7.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Billion) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Billion) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East & Africa (MEA)
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. The US
9.2.1.2. Canada
9.2.2. By COPD Type
9.2.3. By Treatment Type
9.2.4. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By COPD Type
9.3.3. By Treatment Type
9.3.4. By End User
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By COPD Type
10.2.3. By Treatment Type
10.2.4. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By COPD Type
10.3.3. By Treatment Type
10.3.4. By End User
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. The UK
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By COPD Type
11.2.3. By Treatment Type
11.2.4. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By COPD Type
11.3.3. By Treatment Type
11.3.4. By End User
11.4. Key Takeaways
12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.1.4. Singapore
12.2.1.5. Thailand
12.2.1.6. Indonesia
12.2.1.7. Australia
12.2.1.8. New Zealand
12.2.1.9. Rest of Asia Pacific
12.2.2. By COPD Type
12.2.3. By Treatment Type
12.2.4. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By COPD Type
12.3.3. By Treatment Type
12.3.4. By End User
12.4. Key Takeaways
13. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. GCC Countries
13.2.1.2. South Africa
13.2.1.3. Israel
13.2.1.4. Rest of MEA
13.2.2. By COPD Type
13.2.3. By Treatment Type
13.2.4. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By COPD Type
13.3.3. By Treatment Type
13.3.4. By End User
13.4. Key Takeaways
14. Key Countries Market Analysis
14.1. U.S.
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2022
14.1.2.1. By COPD Type
14.1.2.2. By Treatment Type
14.1.2.3. By End User
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2022
14.2.2.1. By COPD Type
14.2.2.2. By Treatment Type
14.2.2.3. By End User
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2022
14.3.2.1. By COPD Type
14.3.2.2. By Treatment Type
14.3.2.3. By End User
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2022
14.4.2.1. By COPD Type
14.4.2.2. By Treatment Type
14.4.2.3. By End User
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2022
14.5.2.1. By COPD Type
14.5.2.2. By Treatment Type
14.5.2.3. By End User
14.6. The UK.
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2022
14.6.2.1. By COPD Type
14.6.2.2. By Treatment Type
14.6.2.3. By End User
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2022
14.7.2.1. By COPD Type
14.7.2.2. By Treatment Type
14.7.2.3. By End User
14.8. Spain
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2022
14.8.2.1. By COPD Type
14.8.2.2. By Treatment Type
14.8.2.3. By End User
14.9. Italy
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2022
14.9.2.1. By COPD Type
14.9.2.2. By Treatment Type
14.9.2.3. By End User
14.10. China
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2022
14.10.2.1. By COPD Type
14.10.2.2. By Treatment Type
14.10.2.3. By End User
14.11. Japan
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2022
14.11.2.1. By COPD Type
14.11.2.2. By Treatment Type
14.11.2.3. By End User
14.12. South Korea
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2022
14.12.2.1. By COPD Type
14.12.2.2. By Treatment Type
14.12.2.3. By End User
14.13. Singapore
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2022
14.13.2.1. By COPD Type
14.13.2.2. By Treatment Type
14.13.2.3. By End User
14.14. Thailand
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2022
14.14.2.1. By COPD Type
14.14.2.2. By Treatment Type
14.14.2.3. By End User
14.15. Indonesia
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2022
14.15.2.1. By COPD Type
14.15.2.2. By Treatment Type
14.15.2.3. By End User
14.16. Australia
14.16.1. Pricing Analysis
14.16.2. Market Share Analysis, 2022
14.16.2.1. By COPD Type
14.16.2.2. By Treatment Type
14.16.2.3. By End User
14.17. New Zealand
14.17.1. Pricing Analysis
14.17.2. Market Share Analysis, 2022
14.17.2.1. By COPD Type
14.17.2.2. By Treatment Type
14.17.2.3. By End User
14.18. GCC Countries
14.18.1. Pricing Analysis
14.18.2. Market Share Analysis, 2022
14.18.2.1. By COPD Type
14.18.2.2. By Treatment Type
14.18.2.3. By End User
14.19. South Africa
14.19.1. Pricing Analysis
14.19.2. Market Share Analysis, 2022
14.19.2.1. By COPD Type
14.19.2.2. By Treatment Type
14.19.2.3. By End User
14.20. Israel
14.20.1. Pricing Analysis
14.20.2. Market Share Analysis, 2022
14.20.2.1. By COPD Type
14.20.2.2. By Treatment Type
14.20.2.3. By End User
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By COPD Type
15.3.3. By Treatment Type
15.3.4. By End User
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. Abbott
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.2. AstraZeneca
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.3. Dr. Reddy’s Laboratories Ltd
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.4. F. Hoffmann-La Roche Ltd
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.5. GSK
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.6. Merck
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.7. Novartis AG
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.8. Pfizer Inc
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.9. GlaxoSmithKline
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.10. Chiesi Farmaceutici S.p.A
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
16.1.11. Boehringer Ingelheim Pharmaceuticals
16.1.11.1. Overview
16.1.11.2. Product Portfolio
16.1.11.3. Profitability by Market Segments
16.1.11.4. Sales Footprint
16.1.11.5. Strategy Overview
16.1.11.5.1. Marketing Strategy
16.1.12. Sunovion Pharmaceuticals
16.1.12.1. Overview
16.1.12.2. Product Portfolio
16.1.12.3. Profitability by Market Segments
16.1.12.4. Sales Footprint
16.1.12.5. Strategy Overview
16.1.12.5.1. Marketing Strategy
17. Assumptions & Acronyms Used18. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Billion) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Billion) Forecast by COPD Type, 2018 to 2033
Table 3: Global Market Value (US$ Billion) Forecast by Treatment Type, 2018 to 2033
Table 4: Global Market Value (US$ Billion) Forecast by End User, 2018 to 2033
Table 5: North America Market Value (US$ Billion) Forecast by Country, 2018 to 2033
Table 6: North America Market Value (US$ Billion) Forecast by COPD Type, 2018 to 2033
Table 7: North America Market Value (US$ Billion) Forecast by Treatment Type, 2018 to 2033
Table 8: North America Market Value (US$ Billion) Forecast by End User, 2018 to 2033
Table 9: Latin America Market Value (US$ Billion) Forecast by Country, 2018 to 2033
Table 10: Latin America Market Value (US$ Billion) Forecast by COPD Type, 2018 to 2033
Table 11: Latin America Market Value (US$ Billion) Forecast by Treatment Type, 2018 to 2033
Table 12: Latin America Market Value (US$ Billion) Forecast by End User, 2018 to 2033
Table 13: Europe Market Value (US$ Billion) Forecast by Country, 2018 to 2033
Table 14: Europe Market Value (US$ Billion) Forecast by COPD Type, 2018 to 2033
Table 15: Europe Market Value (US$ Billion) Forecast by Treatment Type, 2018 to 2033
Table 16: Europe Market Value (US$ Billion) Forecast by End User, 2018 to 2033
Table 17: Asia Pacific Market Value (US$ Billion) Forecast by Country, 2018 to 2033
Table 18: Asia Pacific Market Value (US$ Billion) Forecast by COPD Type, 2018 to 2033
Table 19: Asia Pacific Market Value (US$ Billion) Forecast by Treatment Type, 2018 to 2033
Table 20: Asia Pacific Market Value (US$ Billion) Forecast by End User, 2018 to 2033
Table 21: MEA Market Value (US$ Billion) Forecast by Country, 2018 to 2033
Table 22: MEA Market Value (US$ Billion) Forecast by COPD Type, 2018 to 2033
Table 23: MEA Market Value (US$ Billion) Forecast by Treatment Type, 2018 to 2033
Table 24: MEA Market Value (US$ Billion) Forecast by End User, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Billion) by COPD Type, 2023 to 2033
Figure 2: Global Market Value (US$ Billion) by Treatment Type, 2023 to 2033
Figure 3: Global Market Value (US$ Billion) by End User, 2023 to 2033
Figure 4: Global Market Value (US$ Billion) by Region, 2023 to 2033
Figure 5: Global Market Value (US$ Billion) Analysis by Region, 2018 to 2033
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 8: Global Market Value (US$ Billion) Analysis by COPD Type, 2018 to 2033
Figure 9: Global Market Value Share (%) and BPS Analysis by COPD Type, 2023 to 2033
Figure 10: Global Market Y-o-Y Growth (%) Projections by COPD Type, 2023 to 2033
Figure 11: Global Market Value (US$ Billion) Analysis by Treatment Type, 2018 to 2033
Figure 12: Global Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 13: Global Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 14: Global Market Value (US$ Billion) Analysis by End User, 2018 to 2033
Figure 15: Global Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 16: Global Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 17: Global Market Attractiveness by COPD Type, 2023 to 2033
Figure 18: Global Market Attractiveness by Treatment Type, 2023 to 2033
Figure 19: Global Market Attractiveness by End User, 2023 to 2033
Figure 20: Global Market Attractiveness by Region, 2023 to 2033
Figure 21: North America Market Value (US$ Billion) by COPD Type, 2023 to 2033
Figure 22: North America Market Value (US$ Billion) by Treatment Type, 2023 to 2033
Figure 23: North America Market Value (US$ Billion) by End User, 2023 to 2033
Figure 24: North America Market Value (US$ Billion) by Country, 2023 to 2033
Figure 25: North America Market Value (US$ Billion) Analysis by Country, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 28: North America Market Value (US$ Billion) Analysis by COPD Type, 2018 to 2033
Figure 29: North America Market Value Share (%) and BPS Analysis by COPD Type, 2023 to 2033
Figure 30: North America Market Y-o-Y Growth (%) Projections by COPD Type, 2023 to 2033
Figure 31: North America Market Value (US$ Billion) Analysis by Treatment Type, 2018 to 2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 34: North America Market Value (US$ Billion) Analysis by End User, 2018 to 2033
Figure 35: North America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 37: North America Market Attractiveness by COPD Type, 2023 to 2033
Figure 38: North America Market Attractiveness by Treatment Type, 2023 to 2033
Figure 39: North America Market Attractiveness by End User, 2023 to 2033
Figure 40: North America Market Attractiveness by Country, 2023 to 2033
Figure 41: Latin America Market Value (US$ Billion) by COPD Type, 2023 to 2033
Figure 42: Latin America Market Value (US$ Billion) by Treatment Type, 2023 to 2033
Figure 43: Latin America Market Value (US$ Billion) by End User, 2023 to 2033
Figure 44: Latin America Market Value (US$ Billion) by Country, 2023 to 2033
Figure 45: Latin America Market Value (US$ Billion) Analysis by Country, 2018 to 2033
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 48: Latin America Market Value (US$ Billion) Analysis by COPD Type, 2018 to 2033
Figure 49: Latin America Market Value Share (%) and BPS Analysis by COPD Type, 2023 to 2033
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by COPD Type, 2023 to 2033
Figure 51: Latin America Market Value (US$ Billion) Analysis by Treatment Type, 2018 to 2033
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 54: Latin America Market Value (US$ Billion) Analysis by End User, 2018 to 2033
Figure 55: Latin America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 57: Latin America Market Attractiveness by COPD Type, 2023 to 2033
Figure 58: Latin America Market Attractiveness by Treatment Type, 2023 to 2033
Figure 59: Latin America Market Attractiveness by End User, 2023 to 2033
Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 61: Europe Market Value (US$ Billion) by COPD Type, 2023 to 2033
Figure 62: Europe Market Value (US$ Billion) by Treatment Type, 2023 to 2033
Figure 63: Europe Market Value (US$ Billion) by End User, 2023 to 2033
Figure 64: Europe Market Value (US$ Billion) by Country, 2023 to 2033
Figure 65: Europe Market Value (US$ Billion) Analysis by Country, 2018 to 2033
Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 68: Europe Market Value (US$ Billion) Analysis by COPD Type, 2018 to 2033
Figure 69: Europe Market Value Share (%) and BPS Analysis by COPD Type, 2023 to 2033
Figure 70: Europe Market Y-o-Y Growth (%) Projections by COPD Type, 2023 to 2033
Figure 71: Europe Market Value (US$ Billion) Analysis by Treatment Type, 2018 to 2033
Figure 72: Europe Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 73: Europe Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 74: Europe Market Value (US$ Billion) Analysis by End User, 2018 to 2033
Figure 75: Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 76: Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 77: Europe Market Attractiveness by COPD Type, 2023 to 2033
Figure 78: Europe Market Attractiveness by Treatment Type, 2023 to 2033
Figure 79: Europe Market Attractiveness by End User, 2023 to 2033
Figure 80: Europe Market Attractiveness by Country, 2023 to 2033
Figure 81: Asia Pacific Market Value (US$ Billion) by COPD Type, 2023 to 2033
Figure 82: Asia Pacific Market Value (US$ Billion) by Treatment Type, 2023 to 2033
Figure 83: Asia Pacific Market Value (US$ Billion) by End User, 2023 to 2033
Figure 84: Asia Pacific Market Value (US$ Billion) by Country, 2023 to 2033
Figure 85: Asia Pacific Market Value (US$ Billion) Analysis by Country, 2018 to 2033
Figure 86: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 87: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 88: Asia Pacific Market Value (US$ Billion) Analysis by COPD Type, 2018 to 2033
Figure 89: Asia Pacific Market Value Share (%) and BPS Analysis by COPD Type, 2023 to 2033
Figure 90: Asia Pacific Market Y-o-Y Growth (%) Projections by COPD Type, 2023 to 2033
Figure 91: Asia Pacific Market Value (US$ Billion) Analysis by Treatment Type, 2018 to 2033
Figure 92: Asia Pacific Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 93: Asia Pacific Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 94: Asia Pacific Market Value (US$ Billion) Analysis by End User, 2018 to 2033
Figure 95: Asia Pacific Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 96: Asia Pacific Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 97: Asia Pacific Market Attractiveness by COPD Type, 2023 to 2033
Figure 98: Asia Pacific Market Attractiveness by Treatment Type, 2023 to 2033
Figure 99: Asia Pacific Market Attractiveness by End User, 2023 to 2033
Figure 100: Asia Pacific Market Attractiveness by Country, 2023 to 2033
Figure 101: MEA Market Value (US$ Billion) by COPD Type, 2023 to 2033
Figure 102: MEA Market Value (US$ Billion) by Treatment Type, 2023 to 2033
Figure 103: MEA Market Value (US$ Billion) by End User, 2023 to 2033
Figure 104: MEA Market Value (US$ Billion) by Country, 2023 to 2033
Figure 105: MEA Market Value (US$ Billion) Analysis by Country, 2018 to 2033
Figure 106: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 107: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 108: MEA Market Value (US$ Billion) Analysis by COPD Type, 2018 to 2033
Figure 109: MEA Market Value Share (%) and BPS Analysis by COPD Type, 2023 to 2033
Figure 110: MEA Market Y-o-Y Growth (%) Projections by COPD Type, 2023 to 2033
Figure 111: MEA Market Value (US$ Billion) Analysis by Treatment Type, 2018 to 2033
Figure 112: MEA Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 113: MEA Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 114: MEA Market Value (US$ Billion) Analysis by End User, 2018 to 2033
Figure 115: MEA Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 116: MEA Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 117: MEA Market Attractiveness by COPD Type, 2023 to 2033
Figure 118: MEA Market Attractiveness by Treatment Type, 2023 to 2033
Figure 119: MEA Market Attractiveness by End User, 2023 to 2033
Figure 120: MEA Market Attractiveness by Country, 2023 to 2033
